Cellectis ADR (NASDAQ: CLLS) has experienced a rise in its stock price by 9.18 compared to its previous closing price of 1.96. However, the company has seen a gain of 9.18% in its stock price over the last five trading days. globenewswire.com reported 2024-11-05 that NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) — Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that pre-clinical data to enhance CAR T cell activity against solid tumors while preventing potential toxicity, will be presented at the Society for Immunotherapy of Cancer’s 39th Annual Meeting (SITC), that will take place on November 6-10, 2024 in Houston, Texas.
Is It Worth Investing in Cellectis ADR (NASDAQ: CLLS) Right Now?
CLLS has 36-month beta value of 3.07. Analysts have mixed views on the stock, with 3 analysts rating it as a “buy,” 4 as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CLLS is 69.26M, and currently, short sellers hold a 0.23% ratio of that float. The average trading volume of CLLS on November 27, 2024 was 49.78K shares.
CLLS’s Market Performance
The stock of Cellectis ADR (CLLS) has seen a 9.18% increase in the past week, with a 10.88% rise in the past month, and a -9.70% fall in the past quarter. The volatility ratio for the week is 4.90%, and the volatility levels for the past 30 days are at 5.83% for CLLS. The simple moving average for the past 20 days is 14.09% for CLLS’s stock, with a -8.22% simple moving average for the past 200 days.
Analysts’ Opinion of CLLS
Many brokerage firms have already submitted their reports for CLLS stocks, with Bryan Garnier repeating the rating for CLLS by listing it as a “Buy.” The predicted price for CLLS in the upcoming period, according to Bryan Garnier is $6 based on the research report published on March 17, 2023 of the previous year 2023.
Robert W. Baird, on the other hand, stated in their research note that they expect to see CLLS reach a price target of $10. The rating they have provided for CLLS stocks is “Outperform” according to the report published on May 18th, 2022.
Wells Fargo gave a rating of “Equal Weight” to CLLS, setting the target price at $16 in the report published on January 06th of the previous year.
CLLS Trading at 9.35% from the 50-Day Moving Average
After a stumble in the market that brought CLLS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -43.29% of loss for the given period.
Volatility was left at 5.83%, however, over the last 30 days, the volatility rate increased by 4.90%, as shares surge +16.94% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -8.55% lower at present.
During the last 5 trading sessions, CLLS rose by +9.18%, which changed the moving average for the period of 200-days by -29.37% in comparison to the 20-day moving average, which settled at $1.8800. In addition, Cellectis ADR saw -30.52% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for CLLS
Current profitability levels for the company are sitting at:
- -2.71 for the present operating margin
- 1.04 for the gross margin
The net margin for Cellectis ADR stands at -2.94. The total capital return value is set at -0.34. Equity return is now at value -101.50, with -34.45 for asset returns.
Based on Cellectis ADR (CLLS), the company’s capital structure generated 0.26 points at debt to capital in total, while cash flow to debt ratio is standing at 1.35. The debt to equity ratio resting at 0.36. The interest coverage ratio of the stock is -11.12.
Currently, EBITDA for the company is -92.64 million with net debt to EBITDA at 0.71. When we switch over and look at the enterprise to sales, we see a ratio of 2.64. The receivables turnover for the company is 1.04for trailing twelve months and the total asset turnover is 0.07. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.78.
Conclusion
To put it simply, Cellectis ADR (CLLS) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
